ADAM17

ADAM17 Informations sur la molécule

Nom anglais	Disintegrin and metalloproteinase domain-containing protein 17	Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2	Alias de la cible	EC:3.4.24.86，ADAM17 Protein，ADAM 17，Snake venom-like protease，CSVP，CD156b，ADAM17，ADAM Metallopeptidase Domain 17，TNF-Alpha Convertase，TACE，TNF-Alpha Converting Enzyme，TNF-Alpha-Converting Enzyme，CD156b Antigen，EC 3.4.24.86，NISBD1，NISBD，Disintegrin and metalloproteinase domain-containing protein 17，Tumor Necrosis Factor， Alpha， Converting Enzyme，ADAM Metallopeptidase Domain 18，ADAM18
Phase de R&D la plus avancée	Phase 1 Clinical

Nom anglais	Disintegrin and metalloproteinase domain-containing protein 17
Alias de la cible	EC:3.4.24.86，ADAM17 Protein，ADAM 17，Snake venom-like protease，CSVP，CD156b，ADAM17，ADAM Metallopeptidase Domain 17，TNF-Alpha Convertase，TACE，TNF-Alpha Converting Enzyme，TNF-Alpha-Converting Enzyme，CD156b Antigen，EC 3.4.24.86，NISBD1，NISBD，Disintegrin and metalloproteinase domain-containing protein 17，Tumor Necrosis Factor， Alpha， Converting Enzyme，ADAM Metallopeptidase Domain 18，ADAM18
Nombre de médicaments commercialisés	0
Nombre de médicaments cliniques	2
Phase de R&D la plus avancée	Phase 1 Clinical

ADAM17 Liste de produits

Attribut
Protein (2)
Bibliothèque de produits
En ligne (2)
Espèces
Mouse (1)Human (1)
Étiquette
His Tag (2)
Marqueur
Unconjugated (2)

Numéro de produit	Espèces	Système d'expression	Description du produit	Structure protéique	Pureté	Caractéristiques	Pré-commande/Commande
AD7-H53H3	Human	CHO	Human ADAM17 / TACE / CD156b Protein, His Tag (active enzyme)				Ajouter au panier
AD7-M52H1	Mouse	HEK293	Mouse ADAM17 / TACE / CD156b Protein, His Tag				Ajouter au panier

Quantité totale2

ADAM17Contexte de la molécule

Disintegrin and metalloproteinase domain-containing protein 17 (ADAM17), a member of the ADAM protein family of disintegrins and metalloproteases, is also known as TNF-alpha convertase, TNF-alpha-converting enzyme and CD156b, which contains one disintegrin domain and one peptidase M12B domain. ADAM17 can cleave the membrane-bound precursor of TNF-alpha to its mature soluble form. ADAM17 is also responsible for the proteolytical release of soluble JAM3 from endothelial cells surface (By similarity) and proteolytic release of several other cell-surface proteins, including p75 TNF-receptor, interleukin 1 receptor type II, p55 TNF-receptor, transforming growth factor-alpha, L-selectin, growth hormone receptor, MUC1 and the amyloid precursor protein. Furthermore, ADAM17 acts as an activator of Notch pathway by mediating cleavage of Notch, generating the membrane-associated intermediate fragment called Notch extracellular truncation.

ADAM17Alias de la molécule

ADAM17,TACE,CD156b

Informations sur les médicaments cliniques

Nom anglais	Code de recherche	Phase de R&D	Entreprise	Indication	Essai clinique
Aderbasib	INCB-7839; INC-B007839; INCB-007839	Phase 1 Clinical	Incyte Corp	Astrocytoma; Breast Neoplasms; Diffuse Intrinsic Pontine Glioma; Glioblastoma; Glioma; Lymphoma, Large B-Cell, Diffuse; Neoplasms; Oligodendroglioma; Solid tumours	Details
ORYN-1001	ORTD-1; ORYN-1001	Phase 1 Clinical	Oryn Therapeutics Llc	Arthritis, Rheumatoid; Coronavirus Disease 2019 (COVID-19)	Details